Piper Sandler Maintains Neutral on Silk Road Medical, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains a Neutral rating on Silk Road Medical (NASDAQ:SILK) and raises the price target from $18 to $20.
May 01, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Silk Road Medical and raises the price target from $18 to $20.
The increase in price target by Piper Sandler suggests a positive outlook on Silk Road Medical's stock value in the short term, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100